(P-112) Characterization of Herpes Zoster Cases and Sustained High Vaccine Efficacy Against Herpes Zoster Complications in Individuals Vaccinated with Recombinant Zoster Vaccine During A Long-Term Follow-Up Study

Director, Senior Clinical Sciences Lead
GSK
Wavre, Brabant Wallon, Belgium

Senior Director, Vaccine Value Evidence
GSK
Wavre, Vlaams-Brabant, Belgium

Senior Clinical Research and Development Lead
GSK
Rixensart, Brabant Wallon, Belgium

Director vaccine research department
FISABIO
Valencia, Comunidad Valenciana, Spain

Mr.
GSK
Dublin, Dublin, Ireland

GSK
London, England, United Kingdom

Expert Statistician
GSK
Rockville, Maryland, United States

GSK, Rockville, MD, USA
Rockville, Maryland, United States